The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo

[1]  J. Gills,et al.  Perifosine: Update on a novel Akt inhibitor , 2009, Current oncology reports.

[2]  J. Schellens,et al.  Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. , 2007, Cancer treatment reviews.

[3]  Claus Belka,et al.  The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro , 2006, Radiation oncology.

[4]  J. Schellens,et al.  Radiosensitization of Squamous Cell Carcinoma by the Alkylphospholipid Perifosine in Cell Culture and Xenografts , 2006, Clinical Cancer Research.

[5]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[6]  Yiling Lu,et al.  Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells , 2006, Oncogene.

[7]  K. Bélanger,et al.  Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma , 2005, Investigational New Drugs.

[8]  S. Steinberg,et al.  A phase II study of perifosine in androgen independent prostate cancer , 2005, Cancer biology & therapy.

[9]  M. Birnbaum,et al.  Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. , 2005, Cancer research.

[10]  E. Holland,et al.  Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. , 2005, Cancer research.

[11]  T. Wheeler,et al.  The emerging role of the PI3-K-Akt pathway in prostate cancer progression , 2005, Prostate Cancer and Prostatic Diseases.

[12]  S. Payne,et al.  Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. , 2005, Cancer research.

[13]  M. Krause,et al.  Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  E. Sausville,et al.  In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines , 2004, Clinical Cancer Research.

[15]  Z. Han,et al.  Phosphatidylinositide 3-kinase/AKT in radiation responses. , 2004, Histology and histopathology.

[16]  C. Belka,et al.  Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. , 2004, International journal of radiation oncology, biology, physics.

[17]  R. Handrick,et al.  Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. , 2003, Current medicinal chemistry. Anti-cancer agents.

[18]  P. Vogt,et al.  Oncogenic transformation induced by membrane-targeted Akt2 and Akt3 , 2001, Oncogene.

[19]  J. Lacal,et al.  Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity , 2001, Oncogene.

[20]  S. Zerp,et al.  Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. , 2001, International journal of radiation oncology, biology, physics.

[21]  Faustino Mollinedo,et al.  Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid‐induced apoptosis , 2000, International journal of cancer.

[22]  S. Schwartz,et al.  A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.

[23]  H. Bartelink,et al.  Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. , 1999, Cancer research.

[24]  P. Vogt,et al.  The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. Mollinedo,et al.  Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. , 1998, Molecular pharmacology.

[26]  O. Gründel,et al.  Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Engel,et al.  D-21266, a new heterocyclic alkylphospholipid with antitumour activity. , 1997, European journal of cancer.

[28]  Xiaoping Zhou,et al.  1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. , 1996, The Journal of clinical investigation.

[29]  A. Giuliano,et al.  The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. , 1996, Cancer letters.

[30]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[31]  E. Modest,et al.  Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. , 1992, Cancer research.

[32]  H. Grunicke,et al.  Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. , 1991, Cancer research.

[33]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Anderson,et al.  Radiation Oncology , 2001, Springer International Publishing.